Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4547 + Tislelizumab in FGFR+ Urothelial Carcinoma
NCT05775874Phase 2Recruiting
- Sponsor
- Abbisko Therapeutics
- Start
- Sep 2022
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fexagratinib in urothelial carcinoma (UC), sponsored by Abbisko Therapeutics. Started Sep 2022; status: recruiting.
02
Drugs
fexagratinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05775874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05775874.